Home Health Merck, Moderna Melanoma Vaccine Study Succeeds
Health

Merck, Moderna Melanoma Vaccine Study Succeeds

Key Points

Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest."

Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
Merck (ORG) Moderna Melanoma Vaccine Study (ORG) Moderna (ORG) Madison Muller (PERSON)
Originally published by Bloomberg Markets Read original →